ReviewInternational journal of medical sciences2023
Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages.
Review in International journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Comparing routine hematological parameters on COVID-19, bacterial infections, and coinfection in elderly severe community-acquired pneumonia, a retrospective study in primary hospitals.Journal of family medicine and primary care · 2026Article
- Overview of SARS-CoV-2 genomic surveillance in Central America and the Dominican Republic from February 2020 to January 2023: the impact of PAHO and COMISCA's collaborative efforts.Frontiers in public health · 2026Article
- Article
- 4-Hydroxychalcone Inhibits Human Coronavirus HCoV-OC43 by Targeting EGFR/AKT/ERK1/2 Signaling Pathway.Viruses · 2025Article
- Genomics-based approach for detection and characterization of SARS-CoV-2 co-infections and diverse viral populations.Microbiology spectrum · 2025Article
- Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era.Journal of medical virology · 2025Article
- Enhancement of immunogenicity of SARS-CoV-2 spike protein expressed inFrontiers in microbiology · 2025Article
- Current Updates on Variants of SARS-CoV- 2: Systematic Review.Health science reports · 2024Review
- Immunomodulation of adipose-derived mesenchymal stem cells on peripheral blood mononuclear cells in colorectal cancer patients with COVID-19.World journal of gastrointestinal oncology · 2024Article
- Surfing the Waves of SARS-CoV-2: Analysis of Viral Genome Variants Using an NGS Survey in Verona, Italy.Microorganisms · 2024Article
- Article
- Recombination Events Among SARS-CoV-2 Omicron Subvariants: Impact on Spike Interaction With ACE2 Receptor and Neutralizing Antibodies.Evolutionary bioinformatics online · 2024Article
- Respiratory pathogenic microbial infections: a narrative review.International journal of medical sciences · 2024Review
- Article
- Article
- Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Unraveling the genetic evolution of SARS-CoV-2 Recombinants using mutational dynamics across the different lineages.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 Omicron is currently the predominant circulating variant in the COVID-19 pandemic. The dominating Omicron sublineages respond to host immune pressure and develop advantageous mutations or genetic recombination, which result in variants that are more contagious or better at escaping immune responses in response to previous infection or vaccination. Meanwhile, multiple genetic recombination events have been reported in coinfection cases, the majority of which have resulted from the recombination between co-circulating Omicron BA.1 (or BA.1.1) and Delta variant or BA.2. Here, we review the knowledge and characterization of recombination for SARS-CoV-2 at the population level, provide an update on the occurrence of newly circulating Omicron sublineages, and discuss the effectiveness of novel vaccines/therapeutic drugs against the Omicron variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.